MARKET

IMGN

IMGN

ImmunoGen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.500
-0.050
-1.41%
Opening 11:15 03/31 EDT
OPEN
3.480
PREV CLOSE
3.550
HIGH
3.540
LOW
3.390
VOLUME
455.31K
TURNOVER
--
52 WEEK HIGH
7.07
52 WEEK LOW
1.760
MARKET CAP
610.12M
P/E (TTM)
-4.9758
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of IMGN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average IMGN stock price target is 6.70 with a high estimate of 9.00 and a low estimate of 4.000.

EPS

IMGN News

More
  • ImmunoGen: Tremendous Value In Your Turnaround Stock
  • Seeking Alpha - Article · 5d ago
  • Why Is ImmunoGen (IMGN) Down 45.5% Since Last Earnings Report?
  • Zacks · 03/15 16:30
  • Edited Transcript of IMGN earnings conference call or presentation 14-Feb-20 1:00pm GMT
  • Thomson Reuters StreetEvents · 02/21 10:44
  • ImmunoGen: A Potential Turnaround Story For 2020
  • Seeking Alpha - Article · 02/21 07:26

Industry

Biotechnology & Medical Research
-0.47%
Pharmaceuticals & Medical Research
-0.31%

Hot Stocks

Symbol
Price
%Change

About IMGN

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs.
More

Webull offers kinds of ImmunoGen, Inc. stock information, including NASDAQ:IMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMGN stock news, and many more online research tools to help you make informed decisions.